{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:55:10Z","timestamp":1793314510749,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,11,15]],"date-time":"2012-11-15T00:00:00Z","timestamp":1352937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00520-012-1645-y","type":"journal-article","created":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T02:08:32Z","timestamp":1352858912000},"page":"1167-1174","source":"Crossref","is-referenced-by-count":59,"title":["Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review"],"prefix":"10.1007","volume":"21","author":[{"given":"Durga S.","family":"Borkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Basti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,15]]},"reference":[{"key":"1645_CR1","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/JTO.0b013e3181f1c7b0","volume":"5","author":"M Reck","year":"2010","unstructured":"Reck M, van Zandwijk N, Gridelli C et al (2010) Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV tarceva lung cancer survival treatment study. J Thorac Oncol 5:1616\u20131622","journal-title":"J Thorac Oncol"},{"key":"1645_CR2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123\u2013132","journal-title":"N Engl J Med"},{"key":"1645_CR3","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol 25:1960\u20131966","journal-title":"J Clin Oncol"},{"key":"1645_CR4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337\u2013345","journal-title":"N Engl J Med"},{"key":"1645_CR5","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase iii study of panitumumab with fluorouracil, leucovorin, and irinotecan (folfiri) compared with folfiri alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706\u20134713","journal-title":"J Clin Oncol"},{"key":"1645_CR6","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Cutsem Van","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658\u20131664","journal-title":"J Clin Oncol"},{"key":"1645_CR7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/cncr.22088","volume":"107","author":"DT Milton","year":"2006","unstructured":"Milton DT, Azzoli CG, Heelan RT et al (2006) A phase I\/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 107:1034\u20131041","journal-title":"Cancer"},{"key":"1645_CR8","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947\u2013957","journal-title":"N Engl J Med"},{"key":"1645_CR9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/bjo.78.3.163","volume":"78","author":"K Yamaguchi","year":"1994","unstructured":"Yamaguchi K, Mochizuki M, Watanabe T et al (1994) Human T lymphotropic virus type 1 uveitis after Graves' disease. Br J Ophthalmol 78:163\u2013166","journal-title":"Br J Ophthalmol"},{"key":"1645_CR10","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for her2-positive advanced breast cancer. N Engl J Med 355:2733\u20132743","journal-title":"N Engl J Med"},{"key":"1645_CR11","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","volume":"22","author":"LB Saltz","year":"2004","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ Sr et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201\u20131208","journal-title":"J Clin Oncol"},{"key":"1645_CR12","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","volume":"20","author":"J Baselga","year":"2002","unstructured":"Baselga J, Rischin D, Ranson M et al (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of zd1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292\u20134302","journal-title":"J Clin Oncol"},{"key":"1645_CR13","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","volume":"20","author":"M Ranson","year":"2002","unstructured":"Ranson M, Hammond LA, Ferry D et al (2002) Zd1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20:2240\u20132250","journal-title":"J Clin Oncol"},{"key":"1645_CR14","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","volume":"22","author":"R Perez-Soler","year":"2004","unstructured":"Perez-Soler R, Chachoua A, Hammond LA et al (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238\u20133247","journal-title":"J Clin Oncol"},{"key":"1645_CR15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","volume":"22","author":"D Soulieres","year":"2004","unstructured":"Soulieres D, Senzer NN, Vokes EE et al (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77\u201385","journal-title":"J Clin Oncol"},{"key":"1645_CR16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/15569527.2011.636118","volume":"31","author":"FT Fraunfelder","year":"2012","unstructured":"Fraunfelder FT, Fraunfelder FW (2012) Trichomegaly and other external eye side effects associated with epidermal growth factor. Cutan Ocul Toxicol 31:195\u2013197","journal-title":"Cutan Ocul Toxicol"},{"key":"1645_CR17","first-page":"236","volume":"4","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME, Basti S, Patel J et al (2006) The series clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 4:236\u2013238","journal-title":"J Support Oncol"},{"key":"1645_CR18","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/01.ico.0000214802.40313.fa","volume":"25","author":"A Behrens","year":"2006","unstructured":"Behrens A, Doyle JJ, Stern L et al (2006) Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 25:900\u2013907","journal-title":"Cornea"},{"key":"1645_CR19","first-page":"3639","volume":"23","author":"S Yano","year":"2003","unstructured":"Yano S, Kondo K, Yamaguchi M et al (2003) Distribution and function of egfr in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 23:3639\u20133650","journal-title":"Anticancer Res"},{"key":"1645_CR20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00003226-200101000-00016","volume":"20","author":"Z Liu","year":"2001","unstructured":"Liu Z, Carvajal M, Carraway CA et al (2001) Expression of the receptor tyrosine kinases, epidermal growth factor receptor, erbb2, and erbb3, in human ocular surface epithelia. Cornea 20:81\u201385","journal-title":"Cornea"},{"issue":"Pt 1","key":"1645_CR21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1242\/jcs.106.1.145","volume":"106","author":"JD Zieske","year":"1993","unstructured":"Zieske JD, Wasson M (1993) Regional variation in distribution of EGF receptor in developing and adult corneal epithelium. J Cell Sci 106(Pt 1):145\u2013152","journal-title":"J Cell Sci"},{"key":"1645_CR22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/IOP.0b013e31802d9802","volume":"23","author":"K Lane","year":"2007","unstructured":"Lane K, Goldstein SM (2007) Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg 23:65\u201366","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"1645_CR23","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2004.06265.x","volume":"151","author":"JC Pascual","year":"2004","unstructured":"Pascual JC, Banuls J, Belinchon I et al (2004) Trichomegaly following treatment with gefitinib (zd1839). Br J Dermatol 151:1111\u20131112","journal-title":"Br J Dermatol"},{"key":"1645_CR24","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/annonc\/mdi300","volume":"16","author":"O Bouche","year":"2005","unstructured":"Bouche O, Brixi-Benmansour H, Bertin A et al (2005) Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 16:1711\u20131712","journal-title":"Ann Oncol"},{"key":"1645_CR25","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/ICO.0b013e318064584a","volume":"26","author":"G Zhang","year":"2007","unstructured":"Zhang G, Basti S, Jampol LM (2007) Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature. Cornea 26:858\u2013860","journal-title":"Cornea"},{"key":"1645_CR26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2354.2006.00763.x","volume":"16","author":"B Melichar","year":"2007","unstructured":"Melichar B, Nemcova I (2007) Eye complications of cetuximab therapy. Eur J Cancer Care (Engl) 16:439\u2013443","journal-title":"Eur J Cancer Care (Engl)"},{"key":"1645_CR27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2230.2008.02842.x","volume":"34","author":"M Vaccaro","year":"2009","unstructured":"Vaccaro M, Pollicino A, Barbuzza O et al (2009) Trichomegaly of the eyelashes following treatment with cetuximab. Clin Exp Dermatol 34:402\u2013403","journal-title":"Clin Exp Dermatol"},{"key":"1645_CR28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/ICO.0b013e31818fdbc6","volume":"28","author":"KS Johnson","year":"2009","unstructured":"Johnson KS, Levin F, Chu DS (2009) Persistent corneal epithelial defect associated with erlotinib treatment. Cornea 28:706\u2013707","journal-title":"Cornea"},{"key":"1645_CR29","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/dji104","volume":"97","author":"G Tonini","year":"2005","unstructured":"Tonini G, Vincenzi B, Santini D et al (2005) Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient. J Natl Cancer Inst 97:606\u2013607","journal-title":"J Natl Cancer Inst"},{"key":"1645_CR30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3816\/CCC.2006.n.040","volume":"6","author":"S Dranko","year":"2006","unstructured":"Dranko S, Kinney C, Ramanathan RK (2006) Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer. Clin Colorectal Cancer 6:224\u2013225","journal-title":"Clin Colorectal Cancer"},{"key":"1645_CR31","first-page":"665","volume":"83","author":"MP Ramirez-Soria","year":"2008","unstructured":"Ramirez-Soria MP, Espana-Gregori E, Avino-Martinez J (2008) et al [Blepharitis related to cetuximab treatment in an advanced colorectal cancer patient]. Arch Soc Esp Oftalmologia 83:665\u2013668","journal-title":"Arch Soc Esp Oftalmologia"},{"key":"1645_CR32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/IOP.0b013e31815a124b","volume":"23","author":"BJ Frankfort","year":"2007","unstructured":"Frankfort BJ, Garibaldi DC (2007) Periocular cutaneous toxicity and cicatricial ectropion: a potential class effect of antineoplastic agents that inhibit egfr signaling. Ophthal Plast Reconstr Surg 23:496\u2013497","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"1645_CR33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/IOP.0b013e31802d9025","volume":"23","author":"DC Garibaldi","year":"2007","unstructured":"Garibaldi DC, Adler RA (2007) Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Ophthal Plast Reconstr Surg 23:62\u201363","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"1645_CR34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/IOP.0b013e31802d97f0","volume":"23","author":"AB Methvin","year":"2007","unstructured":"Methvin AB, Gausas RE (2007) Newly recognized ocular side effects of erlotinib. Ophthal Plast Reconstr Surg 23:63\u201365","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"Suppl 1","key":"1645_CR35","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.6004\/jnccn.2009.0074","volume":"7","author":"B Burtness","year":"2009","unstructured":"Burtness B, Anadkat M, Basti S et al (2009) NCCN task force report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 7(Suppl 1):S5\u2013S21, quiz S22-24","journal-title":"J Natl Compr Canc Netw"},{"key":"1645_CR36","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/01.NCC.0000281759.23823.82","volume":"30","author":"S Basti","year":"2007","unstructured":"Basti S (2007) Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs 30:S10\u2013S16","journal-title":"Cancer Nurs"},{"key":"1645_CR37","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/ICO.0b013e318166f483","volume":"27","author":"CG Foerster","year":"2008","unstructured":"Foerster CG, Cursiefen C, Kruse FE (2008) Persisting corneal erosion under cetuximab (erbitux) treatment (epidermal growth factor receptor antibody). Cornea 27:612\u2013614","journal-title":"Cornea"},{"key":"1645_CR38","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","volume":"23","author":"RS Herbst","year":"2005","unstructured":"Herbst RS, Prager D, Hermann R et al (2005) Tribute: a phase III trial of erlotinib hydrochloride (osi-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892\u20135899","journal-title":"J Clin Oncol"},{"key":"1645_CR39","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","volume":"25","author":"U Gatzemeier","year":"2007","unstructured":"Gatzemeier U, Pluzanska A, Szczesna A et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545\u20131552","journal-title":"J Clin Oncol"},{"key":"1645_CR40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1440-1843.2009.01564.x","volume":"14","author":"S Zhou","year":"2009","unstructured":"Zhou S, Ren S, Yan L et al (2009) Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology 14:709\u2013715","journal-title":"Respirology"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1645-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-012-1645-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1645-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T07:59:30Z","timestamp":1643615970000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-012-1645-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,15]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["1645"],"URL":"https:\/\/doi.org\/10.1007\/s00520-012-1645-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,15]]}}}